# Study in Chinese Healthy Adults to Evaluate the Safety, Tolerability and Pharmacokinetics on ZSP1601, and the Effect of Food on ZSP1601 Pharmacokinetics

> **NCT03392779** · PHASE1 · COMPLETED · sponsor: **Guangdong Zhongsheng Pharmaceutical Co., Ltd.** · enrollment: 94 (actual)

## Conditions studied

- Nonalcoholic Steatohepatitis (NASH)

## Interventions

- **DRUG:** ZSP1601 25 mg
- **DRUG:** Placebo 25mg
- **DRUG:** ZSP1601 50 mg
- **DRUG:** Placebo 50 mg
- **DRUG:** ZSP1601 100 mg
- **DRUG:** Placebo 100 mg
- **DRUG:** ZSP1601 175 mg
- **DRUG:** Placebo 175 mg
- **DRUG:** ZSP1601 275 mg
- **DRUG:** Placebo 275 mg
- **DRUG:** ZSP1601 350 mg
- **DRUG:** Placebo 350mg
- **DRUG:** ZSP1601 100 mg
- **DRUG:** Placebo 100mg
- **DRUG:** ZSP1601 50 mg
- **DRUG:** Placebo 50 mg
- **DRUG:** ZSP1601 100 mg
- **DRUG:** Placebo 100 mg

## Key facts

- **NCT ID:** NCT03392779
- **Lead sponsor:** Guangdong Zhongsheng Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-05
- **Primary completion:** 2018-12-21
- **Final completion:** 2019-03-22
- **Target enrollment:** 94 (ACTUAL)
- **Last updated:** 2019-08-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03392779

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03392779, "Study in Chinese Healthy Adults to Evaluate the Safety, Tolerability and Pharmacokinetics on ZSP1601, and the Effect of Food on ZSP1601 Pharmacokinetics". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT03392779. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*